(Q39537308)

English

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

scientific article published on 29 July 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

phase III clinical trial

0 references

Brigitte Dréno

3

object named as

Brigitte Dréno

0 references

Matthew J Wongchenko

object named as

Matthew Wongchenko

15

0 references

Daniil Stroyakovskiy

object named as

Daniil Stroyakovskiy

9

0 references

object named as

Grant A McArthur

2

0 references

Paolo Antonio Ascierto

1

object named as

Paolo A Ascierto

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

20

object named as

Antoni Ribas

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

21

object named as

James Larkin

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

author name string

Victoria Atkinson

4

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Gabrielle Liszkay

5

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Anna Maria Di Giacomo

6

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Mario Mandalà

7

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Lev Demidov

8

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Luc Thomas

10

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Luis de la Cruz-Merino

11

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Caroline Dutriaux

12

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Claus Garbe

13

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Yibing Yan

14

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Ilsung Chang

16

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Jessie J Hsu

17

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Daniel O Koralek

18

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Isabelle Rooney

19

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

29 July 2016

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

1248-1260

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Distinct sets of genetic alterations in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Final version of 2009 AJCC melanoma staging and classification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved overall survival in melanoma with combined dabrafenib and trametinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Sex Steroid Hormone Receptors in Human Thymoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic score for patients with advanced melanoma treated with ipilimumab.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930122-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(16)30122-X

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

release_rxlp4hvtqrajbifdkms6epcaza

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39537308&oldid=1836829318"